ERX-963
/ Expansion Therap
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
March 18, 2021
[VIRTUAL] Results of Double-blind, Placebo-controlled, Dose Range Finding, Crossover Study of Single Day Administration of ERX-963 (IV Flumazenil) in Adults with Myotonic Dystrophy Type 1
(AAN 2021)
- "While ERX-963 at 1 mg and 2 mg was safe, there was no evidence of efficacy in measures of sleepiness or vigilance with this dose and administration regimen."
Clinical • CNS Disorders • Excessive Daytime Sleepiness • Myotonic Dystrophy • Obstructive Sleep Apnea • Sleep Apnea • Sleep Disorder
May 13, 2020
Safety, Tolerability and Pharmacokinetics of ERX-963 in Adults With Myotonic Dystrophy Type 1
(clinicaltrials.gov)
- P1; N=12; Completed; Sponsor: Expansion Therapeutics, Inc.; Active, not recruiting ➔ Completed
Clinical • Trial completion • CNS Disorders • Genetic Disorders • Muscular Atrophy • Myotonic Dystrophy
March 03, 2020
Safety, Tolerability and Pharmacokinetics of ERX-963 in Adults With Myotonic Dystrophy Type 1
(clinicaltrials.gov)
- P1; N=12; Active, not recruiting; Sponsor: Expansion Therapeutics, Inc.; Recruiting ➔ Active, not recruiting
Clinical • Enrollment closed
1 to 3
Of
3
Go to page
1